We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug & Device Products
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Publications
    • Webinar Training Pass
    • eCFR and Guidances
    • Books
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » FDA ISSUES GUIDANCE ON INFORMED CONSENT FOR DIAGNOSTIC STUDIES

FDA ISSUES GUIDANCE ON INFORMED CONSENT FOR DIAGNOSTIC STUDIES

May 5, 2006

The FDA has issued its guidance on informed consent for in vitro diagnostic device studies using unidentifiable biologic material. The guidance is intended to inform sponsors, institutional review boards (IRBs), clinical investigators and agency staff that the FDA will exercise discretion in enforcing its policies on informed consent when human specimens are used for agency-regulated in vitro diagnostic (IVD) device investigations.

The agency "does not intend to object to the use, without informed consent, of leftover human specimens" in investigations that meet investigational device exemption (IDE) criteria, as long as subject privacy is protected by "using only specimens that are not individually identifiable," the guidance states. This includes specimens obtained from repositories and those left over from other, unrelated research.

A specimen is considered to be not individually identifiable when the identity of the subject is not known by the investigator or any other individual associated with the investigation, including the sponsor, the guidance says.

When leftover specimens are available, it is often difficult to locate the donor and obtain consent, the guidance acknowledges. "This difficulty may deter a manufacturer's research efforts [to] bring safe and effective IVDs to market more quickly." Some researchers have indicated that it is unclear how current informed consent policies protect human subjects, and they have suggested that consent issues be addressed through "less burdensome measures," the guidance notes.

The guidance can be viewed at http://www.fda.gov/OHRMS/DOCKETS/98fr/06d-0150-gdl0001.pdf (http://www.fda.gov/OHRMS/DOCKETS/98fr/06d-0150-gdl0001.pdf).

(http://www.fdanews.com/ddl/33_18/)

KEYWORDS FDAnews Device Daily Bulletin

Upcoming Events

  • 08Sep

    Organizing Data and Document Archives: Finding a Needle in a Haystack for FDA Inspections

  • 15Sep

    Califf’s Post-PDUFA, Post-COVID FDA Agenda: Key Developments, Insights and Analysis

  • 20Sep

    Building a World-Class Pharmaceutical Advertising and Promotion Review Program

  • 21Sep

    The FDA’s Focus on Clinical Data Integrity Throughout Product Development and Approval

  • 22Sep

    FDA’s New Quality Management System Regulation: What the Proposed Harmonization with ISO 13485 Means for Devicemakers

  • 11Oct

    1st Annual Quality Management vSummit

Featured Products

  • FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

    FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

  • Selecting and Implementing Electronic Document Management Systems in the EU

    Selecting and Implementing Electronic Document Management Systems in the EU

Featured Stories

  • Hyris T-Cell Test Gains CE-IVD Mark

  • FDA Expands Approval of Bayer’s Nubeqa for Prostate Cancer

  • MicroPort Navibot Receives 510(k) Clearance for Its SkyWalker System

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing